DDInter45 DDInter1631
A phenothiazine derivative that is used as an antipruritic.
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Alimemazine {u} (Compound) resembles {v} (Compound) Acetophenazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orphenadrine
Alimemazine {u} (Compound) resembles {v} (Compound) Pheniramine
Alimemazine {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Alimemazine {u} (Compound) binds {v} (Gene) CYP3A4
Alimemazine {u} (Compound) upregulates {v} (Gene) CHEK2
Alimemazine {u} (Compound) downregulates {v} (Gene) PDHX
Alimemazine {u} (Compound) causes {v} (Side Effect) Respiratory depression
Alimemazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Alimemazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Alimemazine (Compound) resembles Acetophenazine (Compound)
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Alimemazine (Compound) resembles Pheniramine (Compound)
Alimemazine may lead to a major life threatening interaction when taken with Dextropropoxyphene
Alimemazine (Compound) binds CYP3A4 (Gene)
Alimemazine (Compound) upregulates CHEK2 (Gene)
Alimemazine (Compound) downregulates PDHX (Gene)
Alimemazine (Compound) causes Respiratory depression (Side Effect)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate